Pattern of Local Recurrence After I-125 Episcleral Brachytherapy for Uveal Melanoma in a Spanish Referral Ocular Oncology Unit

被引:10
|
作者
Sanchez-Tabernero, Sara [1 ]
Garcia-Alvarez, Ciro [2 ]
Munoz-Moreno, Ma Fe [3 ]
Diezhandino, Patricia [4 ]
Alonso-Martinez, Pilar [4 ]
de Frutos-Baraja, Jesus M. [4 ]
Lopez-Lara, Francisco [4 ]
Saornil, Maria A. [2 ]
机构
[1] Hosp Clin Univ Valladolid, Serv Oftalmol, Av Raman y Cajal 12,8B, Valladolid 47003, Spain
[2] Hosp Clin Univ Valladolid, Serv Oftalmol, Unidad Tumores Intraoculares Adulto, Valladolid, Spain
[3] Hosp Clin Univ Valladolid, Unidad Invest, Unidad Tumores Intraoculares Adulto, Valladolid, Spain
[4] Hosp Clin Univ Valladolid, Serv Oncol Radioterap, Unidad Tumores Intraoculares Adulto, Valladolid, Spain
关键词
COMS RANDOMIZED TRIAL; CILIARY BODY; IODINE-125; BRACHYTHERAPY; CHOROIDAL MELANOMA; TREATMENT FAILURE; SURVIVAL; TUMOR; METASTASIS; PLAQUE; MORTALITY;
D O I
10.1016/j.ajo.2017.05.019
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To describe the time, frequency, and clinical characteristics of treatment failure after I-125 brachytherapy in patients with uveal melanoma treated and followed in a Spanish referral ocular oncology unit. DESIGN: Prospective, consecutive, interventional case series. METHODS: Patients diagnosed with uveal melanoma from 1995 to 2016 and treated with episcleral brachytherapy were included. Demographic data collection, ophthalmic evaluation, ultrasound scan, and systemic studies were performed at baseline, every 6 months thereafter for 5 years, and subsequently at annual intervals. Recurrence was defined as presence of tumor growth after treatment. Baseline analysis was performed by descriptive methods and survival by Kaplan-Meier curves. RESULTS: From 732 patients diagnosed with uveal melanoma, 311 were treated with brachytherapy. In the follow-up (mean 79 months, standard deviation = 55), 16 local tumor recurrences (5.1%) were detected. All relapsing patients had choroidal tumors and 15 presented with visual symptoms. All patients were treated with I-125 brachytherapy, and 2 received associated transpupillary thermotherapy. All the eyes were enucleated after recurrence. Kaplan-Meier analysis showed a mean time of recurrence of 3.7 years (standard deviation = 2.94 years, ranging from 1 to 12 years). Three patients had metastasis in the follow-up. Kaplan-Meier analysis showed worse survival for patients with recurrence. CONCLUSION: Local treatment failure was a relatively infrequent event after I-125 brachytherapy in our series. Recurrences appear not only early but also late in the follow-up. They do not have a distinctive clinical pattern and are associated with poorer survival. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:39 / 45
页数:7
相关论文
共 42 条
  • [31] Reduced blood flow by laser speckle flowgraphy after 125I-plaque brachytherapy for uveal melanoma
    Tamplin, Michelle R.
    Wang, Jui-Kai
    Vitale, Anthony H.
    Hashimoto, Ryuya
    Garvin, Mona K.
    Binkley, Elaine M.
    Hyer, Daniel E.
    Buatti, John M.
    Boldt, H. Culver
    Kardon, Randy H.
    Grumbach, Isabella M.
    BMC OPHTHALMOLOGY, 2022, 22 (01)
  • [32] Outcomes after 125I plaque brachytherapy for ocular melanoma:: The Yale Cancer Center experience
    Galper, S. L.
    Rowe, B. P.
    Colasanto, J.
    Fan, Y.
    Haffty, B. G.
    Dowsett, R.
    Liggett, P. E.
    Decker, R. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S240 - S240
  • [33] Local Recurrence Confirmed by Mapping Biopsy Following I-125 Prostate Brachytherapy With or Without External Beam Radiation Therapy
    Yorozu, A.
    Kota, R.
    Takagawa, Y.
    Saito, S.
    Toya, K.
    Shiraishi, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S137 - S138
  • [34] Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma - I. Visual acuity after 3 years - COMS report no. 16
    Melia, BM
    Abramson, DH
    Albert, DM
    Boldt, HC
    Earle, JD
    Hanson, WF
    Montague, P
    Moy, CS
    Schachat, AP
    Simpson, ER
    Straatsma, BR
    Vine, AK
    Weingeist, TA
    OPHTHALMOLOGY, 2001, 108 (02) : 348 - 366
  • [35] Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study
    Pe'er, J
    Stefani, FH
    Seregard, S
    Kivela, T
    Lommatzsch, P
    Prause, JU
    Sobottka, B
    Damato, B
    Chowers, I
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2001, 85 (10) : 1208 - 1212
  • [36] Application of Hybrid Source in Slotted Plaque Brachytherapy for the Treatment of Uveal Melanoma and Dosimetric Comparison of Plans with I-125 and Pd-103 Sources
    Awan, S.
    Meigooni, A.
    Howard, S.
    Tejwani, A.
    Badkul, R.
    Saleh, H.
    MEDICAL PHYSICS, 2019, 46 (06) : E579 - E579
  • [37] The relationship of radiation dose to critical eye structures to loss of visual acuity after I-125 brachytherapy for choroidal melanoma
    Melia, M
    Followill, DS
    Earle, JD
    Krintz, AL
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U685 - U685
  • [38] Local Control, Patterns of Failure, and Visual Acuity following Treatment of Ocular Melanoma Utilizing a 125I Episcleral Plaque: A Single Surgeon Experience
    Karlovits, S.
    Karlovits, B. J.
    Wong, M.
    Trombetta, M. G.
    Johnson, M.
    Verstraeten, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S256 - S256
  • [39] LOW DOSE BRACHYTHERAPY WITH I125 IN PATIENTS WITH LOCAL PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY.
    Gomez Veiga, F. G.
    Gomez, Marino A., I
    Castelo, L. A.
    Gonzalez, Dacal J.
    Lopez, D.
    Ponce, J.
    Candal, A.
    Chantada, V
    JOURNAL OF UROLOGY, 2010, 183 (04): : E232 - E232
  • [40] Pilot Study On Critical Structure Dosing for Ocular Melanoma Radiation Techniques: An Analysis of I-125 Brachytherapy Plaque and Dedicated Proton Eye Beamline Treatment Planning Dosimetry
    Scholey, J.
    Weinberg, V.
    Daftari, I.
    Mishra, K.
    MEDICAL PHYSICS, 2019, 46 (06) : E594 - E595